Titre : Ellipticines

Ellipticines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Double-Blind Method
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Ellipticines : Questions médicales les plus fréquentes", "headline": "Ellipticines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Ellipticines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-02", "dateModified": "2025-03-29", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Ellipticines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Carbazoles", "url": "https://questionsmedicales.fr/mesh/D002227", "about": { "@type": "MedicalCondition", "name": "Carbazoles", "code": { "@type": "MedicalCode", "code": "D002227", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.300.148" } } }, "about": { "@type": "MedicalCondition", "name": "Ellipticines", "alternateName": "Ellipticines", "code": { "@type": "MedicalCode", "code": "D004611", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elaine C O'Sullivan", "url": "https://questionsmedicales.fr/author/Elaine%20C%20O%27Sullivan", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland." } }, { "@type": "Person", "name": "Florence O McCarthy", "url": "https://questionsmedicales.fr/author/Florence%20O%20McCarthy", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland." } }, { "@type": "Person", "name": "Hao Lu", "url": "https://questionsmedicales.fr/author/Hao%20Lu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China." } }, { "@type": "Person", "name": "Manli Liu", "url": "https://questionsmedicales.fr/author/Manli%20Liu", "affiliation": { "@type": "Organization", "name": "Hubei Biopesticide Engineering Research Centre, Hubei Academy of Agricultural Sciences, Wuhan, China." } }, { "@type": "Person", "name": "Wenjia Lu", "url": "https://questionsmedicales.fr/author/Wenjia%20Lu", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Evaluating the effectiveness of stromal-vascular fraction (SVF) cells along with subcision method in the treatment of acne scars: A double-blind randomized controlled clinical trial study.", "datePublished": "2022-09-26", "url": "https://questionsmedicales.fr/article/36086927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocd.15375" } }, { "@type": "ScholarlyArticle", "name": "ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.", "datePublished": "2022-12-20", "url": "https://questionsmedicales.fr/article/36600424", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-067251" } }, { "@type": "ScholarlyArticle", "name": "Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.", "datePublished": "2022-05-23", "url": "https://questionsmedicales.fr/article/35617986", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2213-2600(22)00088-1" } }, { "@type": "ScholarlyArticle", "name": "Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.", "datePublished": "2024-08-14", "url": "https://questionsmedicales.fr/article/39161682", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/DDDT.S472651" } }, { "@type": "ScholarlyArticle", "name": "Efficacy of Liposomal Melatonin in sleep EEG in Childhood: A Double Blind Case Control Study.", "datePublished": "2022-12-29", "url": "https://questionsmedicales.fr/article/36612875", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijerph20010552" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérocycliques 3 noyaux", "item": "https://questionsmedicales.fr/mesh/D006575" }, { "@type": "ListItem", "position": 5, "name": "Carbazoles", "item": "https://questionsmedicales.fr/mesh/D002227" }, { "@type": "ListItem", "position": 6, "name": "Ellipticines", "item": "https://questionsmedicales.fr/mesh/D004611" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Ellipticines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Ellipticines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-12", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Ellipticines", "description": "Comment diagnostiquer une tumeur sensible aux ellipticines ?\nQuels tests sont utilisés pour évaluer l'efficacité des ellipticines ?\nLes ellipticines sont-elles utilisées pour tous les types de cancer ?\nQuels signes cliniques indiquent un traitement par ellipticines ?\nComment évaluer les effets secondaires des ellipticines ?", "url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Double-Blind+Method&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Ellipticines", "description": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?\nLes ellipticines provoquent-elles des effets secondaires ?\nComment reconnaître une réaction allergique aux ellipticines ?\nLes ellipticines affectent-elles le système immunitaire ?\nQuels signes indiquent une toxicité des ellipticines ?", "url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Double-Blind+Method&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Ellipticines", "description": "Peut-on prévenir les cancers traités par ellipticines ?\nQuels facteurs de risque sont associés aux cancers traités par ellipticines ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?\nComment un mode de vie sain influence-t-il le risque de cancer ?\nLes examens de santé réguliers sont-ils importants ?", "url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Double-Blind+Method&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Ellipticines", "description": "Comment les ellipticines sont-elles administrées ?\nLes ellipticines sont-elles utilisées en monothérapie ?\nQuel est le mécanisme d'action des ellipticines ?\nQuelles sont les alternatives aux ellipticines ?\nComment surveiller l'efficacité du traitement par ellipticines ?", "url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Double-Blind+Method&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Ellipticines", "description": "Quelles complications peuvent survenir avec les ellipticines ?\nLes ellipticines peuvent-elles causer des dommages aux organes ?\nComment gérer les effets secondaires graves des ellipticines ?\nLes ellipticines augmentent-elles le risque de récidive du cancer ?\nQuels sont les risques de surdosage d'ellipticines ?", "url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Double-Blind+Method&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Ellipticines", "description": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?\nL'hérédité joue-t-elle un rôle dans le risque de cancer ?\nL'alimentation influence-t-elle le risque de cancer ?\nLe stress est-il un facteur de risque pour le cancer ?\nLes infections virales augmentent-elles le risque de cancer ?", "url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Double-Blind+Method&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une tumeur sensible aux ellipticines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un diagnostic est établi par biopsie et analyses histopathologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'efficacité des ellipticines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie comme l'IRM et des marqueurs tumoraux sont utilisés." } }, { "@type": "Question", "name": "Les ellipticines sont-elles utilisées pour tous les types de cancer ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles sont principalement efficaces contre certains cancers comme le cancer du poumon." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent un traitement par ellipticines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des signes de progression tumorale ou de résistance aux autres traitements peuvent indiquer leur utilisation." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des ellipticines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont évalués par des examens cliniques et des questionnaires de qualité de vie." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, fatigue, perte de poids et changements d'appétit." } }, { "@type": "Question", "name": "Les ellipticines provoquent-elles des effets secondaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent causer nausées, vomissements, et troubles hématologiques." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique aux ellipticines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Les ellipticines affectent-elles le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner une immunosuppression, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels signes indiquent une toxicité des ellipticines ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes de toxicité incluent fatigue extrême, saignements inhabituels et jaunisse." } }, { "@type": "Question", "name": "Peut-on prévenir les cancers traités par ellipticines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures préventives incluent un mode de vie sain et des dépistages réguliers." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés aux cancers traités par ellipticines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le tabagisme, l'exposition à des agents carcinogènes et des antécédents familiaux." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancer." } }, { "@type": "Question", "name": "Comment un mode de vie sain influence-t-il le risque de cancer ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant alimentation équilibrée et exercice, peut réduire le risque." } }, { "@type": "Question", "name": "Les examens de santé réguliers sont-ils importants ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils permettent de détecter précocement des anomalies et d'initier un traitement rapide." } }, { "@type": "Question", "name": "Comment les ellipticines sont-elles administrées ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont généralement administrées par voie intraveineuse ou orale." } }, { "@type": "Question", "name": "Les ellipticines sont-elles utilisées en monothérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être utilisées seules ou en association avec d'autres traitements anticancéreux." } }, { "@type": "Question", "name": "Quel est le mécanisme d'action des ellipticines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Elles agissent en interférant avec l'ADN des cellules cancéreuses, inhibant leur prolifération." } }, { "@type": "Question", "name": "Quelles sont les alternatives aux ellipticines ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les alternatives incluent d'autres chimiothérapies, thérapies ciblées et immunothérapies." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement par ellipticines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est surveillée par des examens d'imagerie et des bilans sanguins réguliers." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les ellipticines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des saignements et des réactions allergiques." } }, { "@type": "Question", "name": "Les ellipticines peuvent-elles causer des dommages aux organes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des toxicités hépatiques et rénales, nécessitant une surveillance." } }, { "@type": "Question", "name": "Comment gérer les effets secondaires graves des ellipticines ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut l'ajustement de la dose, l'utilisation de médicaments symptomatiques et le suivi." } }, { "@type": "Question", "name": "Les ellipticines augmentent-elles le risque de récidive du cancer ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire le risque de récidive, mais un suivi régulier est essentiel." } }, { "@type": "Question", "name": "Quels sont les risques de surdosage d'ellipticines ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le surdosage peut entraîner des effets toxiques graves, nécessitant une intervention médicale immédiate." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux facteurs incluent le tabagisme, l'exposition à des produits chimiques et l'âge." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans le risque de cancer ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer augmentent le risque de développer certaines tumeurs." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque de cancer ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en fruits et légumes peut réduire le risque de certains cancers." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque pour le cancer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Bien que le stress ne soit pas un facteur direct, il peut affecter le système immunitaire." } }, { "@type": "Question", "name": "Les infections virales augmentent-elles le risque de cancer ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections virales, comme le HPV, sont liées à un risque accru de cancer." } } ] } ] }

Sources (10000 au total)

Evaluating the effectiveness of stromal-vascular fraction (SVF) cells along with subcision method in the treatment of acne scars: A double-blind randomized controlled clinical trial study.

Subcision method is one of the main techniques for treatment of acne scars or stromal-vascular fraction (SVF) and combined therapy can improve treatment strategy.... To use subcision method along with SVF for treatment of acne scar and comprised with alone subcision method.... In this double-blind clinical trial study, 10 patients with acne scars were entered into the study. Subcision technique was randomly performed on one side of the face and subcision technique plus SVF ... In terms of volume and area of scars, the mean percent change was 46.55 ± 13.92 and 44.60 ± 5.76, for the case group, and 13.31 ± 9.27 and 11.28 ± 9.64 for the control group, respectively. So, combine... According to the acquired results, combined therapy can be considered as effective and safe treatment for acne scars with significant higher efficacy compared with subcision alone....

ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.

Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the on... ImmunoSep is a randomised placebo-controlled phase 2 clinical trial with a double-dummy design in which the effect of precision immunotherapy on sepsis phenotypes with MALS and immunoparalysis is stud... The protocol is approved by the German Federal Institute for Drugs and Medical Devices; the National Ethics Committee of Greece and by the National Organization for Medicines of Greece; the Central Co... NCT04990232....

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.

Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone p... In this randomised, double-blind, double placebo-controlled trial, patients were enrolled at 67 trial sites in the USA (60 sites), South Korea (two sites), Mexico (two sites), Singapore (two sites), a... Between Dec 1, 2020, and April 13, 2021, 1047 patients were assessed for eligibility. 1010 patients were enrolled and randomly assigned, 516 (51%) to baricitinib plus remdesivir plus placebo and 494 (... In hospitalised patients with COVID-19 requiring supplemental oxygen by low-flow, high-flow, or non-invasive ventilation, baricitinib plus remdesivir and dexamethasone plus remdesivir resulted in simi... National Institute of Allergy and Infectious Diseases....

Comparison Between Esketamine and Alfentanil for Hysteroscopy: A Prospective, Double-Blind, Randomized Controlled Trial.

This study aimed to establish the 95% effective dose (ED95) of esketamine in combination with propofol for hysteroscopy and then to evaluate its efficacy and safety profile.... This prospective, double-blind, randomized controlled trial consisted of two cohorts. In cohort 1, 45 women aged 18-65 years undergoing hysteroscopy were randomly assigned to either group E (esketamin... The ED95 of esketamine was 0.254 mg/kg (95% CI: 0.214-1.004), while that of alfentanil was 9.121 μg/kg (95% CI: 8.479-13.364). The anesthesia success rate was 93.0% in group E and 95.2% in group A (p ... This study determined the ED 95 dose of esketamine for intravenous general anesthesia during hysteroscopy. Esketamine showed less respiratory and hemodynamic depression, as well as fewer adverse effec... www.chictr.org.cn, (ChiCTR2300077283); registered November 3, 2023....

A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.

Rescue of mitochondrial function is a promising neuroprotective strategy for Parkinson's disease (PD). Ursodeoxycholic acid (UDCA) has shown considerable promise as a mitochondrial rescue agent across... To investigate the safety and tolerability of high-dose UDCA in PD and determine midbrain target engagement.... The UP (UDCA in PD) study was a phase II, randomized, double-blind, placebo-controlled trial of UDCA (30 mg/kg daily, 2:1 randomization UDCA vs. placebo) in 30 participants with PD for 48 weeks. The p... UDCA was safe and well tolerated, and only mild transient gastrointestinal adverse events were more frequent in the UDCA treatment group. Midbrain... High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wile...

Intravenous vitamin C for vasoplegia: A double-blinded randomised clinical trial (VALENCIA trial).

To determine whether intravenous vitamin C compared with placebo, reduces vasopressor requirements in patients with vasoplegic shock.... Double-blinded, randomised clinical trial (RCT) conducted in two intensive care units in Perth, Australia. Vasopressor requirements at enrolment needed to be >10 μg/min noradrenaline after hypovolaemi... Of the 71 patients randomised (35 vitamin C, 36 placebo group), the median vasopressor duration was 44 h [95% CI, 37-54 h] and 55 h [95% CI, 33-66 h]) in the vitamin C and placebo groups (p = 0.057). ... In this RCT of patients with vasoplegic shock of at least moderate severity, the use of IV vitamin C compared with placebo did not significantly reduce the duration of vasopressors.... Prospective registration - trial number ACTRN12617001392358....

Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety.

Fibrotic hypersensitivity pneumonitis (FHP) is an irreversible lung disease with high morbidity and mortality. We sought to evaluate the safety and effect of pirfenidone on disease progression in such... We conducted a single-centre, randomised, double-blinded, placebo-controlled trial in adults with FHP and disease progression. Patients were assigned in a 2:1 ratio to receive either oral pirfenidone ... After randomising 40 patients, enrolment was interrupted by the COVID-19 pandemic. There was no significant between-group difference in FVC% at week 52 (mean difference -0.76%, 95% CI -6.34 to 4.82). ... The trial was underpowered to detect a difference in the primary end point. Pirfenidone was found to be safe and improved PFS in patients with FHP.... NCT02958917....

Comparison of intravenous ibuprofen and tenoxicam efficiency in ankle injury: a randomized, double-blind study.

Pain after soft tissue injuries in and around the ankle is a troublesome process in terms of patient comfort and mobilization. The aim of this study was to compare the analgesic efficacy of intravenou... We conducted a prospective, double-blind, randomized controlled study in a tertiary hospital. The patients were divided into two groups as those administered IV 400 mg ibuprofen and IV 20 mg tenoxicam... One hundred and twenty-four patients were included in the study. There were 62 patients in the tenoxicam group and 62 patients in the ibuprofen group. When VAS scores were compared, it was found that ...